"We welcome yesterday's announcement by Health Canada to enact the new Access to Cannabis for Medical Purposes Regulations, and reintroduce home gardens and caregiver production for authorized patients. This is an important decision, and provides clear direction for the next iteration of our country's evolving framework for medical cannabis, as well as the future of cannabis legalization," said Terry Booth, Aurora CEO.

Aurora's Chief Brand Officer, Neil Belot added, "Aurora has supported patient choice and personal production from day one. We are thrilled with Health Canada's response to the Allard ruling. The ability to choose to grow at home is a great step forward to improving patient access."

Yesterday's announcement and the government's decision demonstrate the significant progress that Canada has made in terms of shifting attitudes, reducing stigma, and recognizing the therapeutic benefits that medical cannabis can provide. Physician support for cannabis as a therapeutic option continues to gain momentum, and demand for Aurora's medical cannabis products has been increasing.

Belot added, "Aurora's premium-quality cannabis, convenient customer service, and affordable prices have so far resulted in over 6,500 patients seeking out cannabis grown and provided under the Aurora Standard. We look forward to applying this same standard to our future home grow solutions for our clients."

In response to the decision and the new market opportunity it will create, Aurora intends to offer authorized clients 360 degree home grow solutions that support the health and safety of Canadians and facilitate the needs of an emerging client base. The offering will include support for safe garden installations, along with a range of genetics, nutrients, lighting equipment, and supplies from Aurora's industry leading partners, such as Gavita and General Hydroponics.

Aurora CEO, Terry Booth, concluded, "We are proud of the progressive attitude our government and institutions are showing in protecting choice and freedom in meeting an important need. Any improvement to safe access resulting from this decision, we believe, is a positive development, and we look forward to working with government officials and industry stakeholders to ensure that Canada remains the global leader in the emerging medical cannabis industry.

About Aurora

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol "ACB".

On behalf of the Board of Directors, AURORA CANNABIS INC.

Terry Booth, CEO

This news release contains statements about the Company's expectations regarding production capacity, production yields and other aspects of its anticipated future operations that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Such factors include but are not limited to the Company's ability to obtain the necessary financing and the general impact of financial market conditions, the yield from marijuana growing operations, product demand, changes in prices of required commodities, competition, government regulations and other risks set out in the Company's management's discussion and analysis filed on SEDAR. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.